The classical pre-metastatic niche paradigm, developed over the past two decades, holds that primary tumors actively prepare distant sites for colonization by releasing soluble factors and extracellular vesicles that travel through the bloodstream and reprogram future metastatic destinations. Bone marrow–derived cells are recruited, blood vessels become leaky and adhesive, immune defenses are suppressed, and the extracellular matrix is degraded and reorganized. What this paradigm does not explain, the review’s authors note, is whether catastrophic systemic inflammation by itself, without any tumor present, can generate similar tissue states. Their answer, assembled from a synthesis of immunological, vascular, and matrix biology, is that it plausibly can, through what they term an Immuno–Vascular–Matrix Triad.

The first arm of the triad is immunological. Sepsis unleashes a storm of damage-associated molecular patterns, including high-mobility group box 1, mitochondrial DNA, and adenosine triphosphate, which flood the circulation as injured cells rupture. These alarmins engage Toll-like receptors, most notably TLR4, on immune and stromal cells, igniting signaling cascades that sustain inflammation well beyond the initial insult. In the acute phase, neutrophils respond with explosive production of neutrophil extracellular traps, web-like lattices of DNA and antimicrobial proteins that normally help contain pathogens. When this NETosis becomes dysregulated, it feeds immunothrombosis, promoting platelet activation and diffuse microthrombosis that choke off capillary beds and create focal pockets of hypoxia throughout the body’s tissues.

Hypoxia is not a passive consequence in this framework but an active remodeling signal. Oxygen-starved regions stabilize hypoxia-inducible factor-1α, a transcription factor that reprograms cellular metabolism and drives angiogenic and pro-adhesive gene expression, echoing the low-oxygen conditions that characterize developing metastatic niches. Meanwhile, the immune system enters a prolonged state of dysfunction that the authors describe as immunodisruption. Lymphopenia, the depletion of circulating lymphocytes, can persist long after a patient has technically recovered. Surviving T cells become exhausted through checkpoint pathways such as PD-1 and CTLA-4, the same molecular brakes that tumors exploit to escape immune attack. Regulatory T cells expand, dampening inflammatory responses but also blunting anti-tumor surveillance, and monocytes lose expression of human leukocyte antigen-DR, impairing their ability to present antigens and coordinate adaptive immunity.

The second arm of the triad concerns the vasculature. Sepsis inflicts direct injury on the endothelium, the single-cell lining of blood vessels that normally acts as a selective barrier and a gatekeeper for immune cell traffic. Glycocalyx degradation, endothelial activation, and increased vascular permeability allow plasma proteins and cells to leak into surrounding tissue. In the pre-metastatic niche literature, vascular leakiness and endothelial hyperadhesiveness are hallmark features that facilitate the extravasation of circulating tumor cells. The review argues that post-sepsis endothelium displays a functionally analogous phenotype: vessels that are more permeable, more adhesive to circulating myeloid cells, and less selective about what crosses them. Persistent recruitment of myeloid cells into tissues, a process sustained by altered chemokine signaling, mirrors the way tumors co-opt bone marrow–derived cells to prepare metastatic sites.

The third arm involves the extracellular matrix, the fibrous scaffold that gives tissues their architecture and mechanical properties. During sepsis, mesenchymal stromal cells and inflammatory extracellular vesicles drive the release of matrix metalloproteinases, enzymes that cleave collagen, laminin, and fibronectin. The result is a matrix that is mechanically unstable, abnormally permeable, and richly pro-adhesive, presenting cryptic binding sites and altered stiffness cues to any cell that encounters it. In established cancer biology, matrix remodeling of this kind lowers the barriers to tumor cell invasion and supports the survival of newly arrived malignant cells. The review proposes that a post-sepsis matrix, transiently or perhaps chronically remodeled, could create comparable conditions of systemic permissiveness, lowering tissue resistance to aberrant cellular persistence of many kinds.

What makes the framework scientifically interesting is its convergence logic. None of the individual components is novel; immunothrombosis, endothelial activation, lymphopenia, and matrix degradation are each well documented in sepsis research. The review’s contribution is to assemble them into a coordinated model and to point out that their combined output, endothelial hyperadhesiveness, reduced immune selectivity, persistent myeloid recruitment, and increased tissue susceptibility, is precisely the functional signature that tumor biologists use to define a pre-metastatic niche. In this reading, sepsis does not cause cancer directly, and the authors are careful to frame the triad as a host-conditioned state of biological plausibility rather than an oncogenic event. The claim is about vulnerability and permissiveness, not causation, and it is explicitly presented as a generator of testable hypotheses rather than a settled conclusion.

That framing matters, because the epidemiological question of whether sepsis survivors face elevated cancer risk remains open and contested in the broader literature. What the review offers is a mechanistic roadmap for investigating that question rigorously. If post-sepsis patients carry measurable, persistent signatures of niche-like priming, elevated circulating markers of endothelial activation, sustained shifts in lymphocyte subsets, altered matrix turnover products, then longitudinal cohort studies could track whether these signatures predict subsequent malignancy diagnoses. Such biomarkers would also serve a second purpose: stratifying the growing population of sepsis survivors, whose numbers have grown as intensive care keeps more patients alive, by their biological risk profile rather than by clinical appearance alone.

The clinical implications extend to post-sepsis recovery monitoring more broadly. Post-sepsis syndrome, encompassing cognitive decline, physical disability, and renewed susceptibility to infection, is increasingly recognized as a major public health burden, yet follow-up care for survivors remains fragmentary in most health systems. If the Immuno–Vascular–Matrix Triad proves measurable in routine clinical practice, it could anchor a new category of surveillance: not merely checking whether organs have recovered their function, but assessing whether tissues have returned to a state of immunological and structural integrity. Interventions that restore immune competence, protect the endothelium, or modulate matrix remodeling could then be evaluated for their ability to reverse primed tissue states before they translate into disease.

The authors are candid about the limits of their synthesis. It is a review, built on mechanistic reasoning across literatures that rarely speak to one another, and it does not present direct experimental evidence that sepsis-primed tissues accept circulating tumor cells more readily. Animal models that induce sepsis and then challenge animals with tumor cell lines would be an obvious next step, as would careful analysis of cancer incidence in large sepsis registries with adequate follow-up and control for confounders such as smoking, comorbidities, and post-sepsis surveillance bias, since survivors undergo more medical attention and thus more diagnosis. Even so, the conceptual payoff is considerable: it reframes sepsis not only as an acute crisis to survive but as a systemic remodeling event whose biological echoes may persist, and it hands researchers a concrete, three-part framework for testing whether the body’s fiercest inflammatory storm can quietly prepare the ground for its next great challenge.

Subject of Research: Post-sepsis tissue remodeling as a mimic of the pre-metastatic niche through immune, vascular, and extracellular matrix alterations

Article Title: Sepsis as a pre-metastatic niche mimic: post-sepsis microenvironmental priming through an Immuno–Vascular–Matrix Triad

Article References: Izquierdo-Condoy, J. S., Saavedra-Torres, J. S., Nati-Castillo, H. A., Gil, J. C., García-Aguilera, M. F., Alexander-León, H. A., Lara Puello, I. M., Vargas Saltos, M., & Ortiz-Prado, E. (2026). Sepsis as a pre-metastatic niche mimic: post-sepsis microenvironmental priming through an Immuno–Vascular–Matrix Triad. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08951-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08951-z

Keywords: sepsis, pre-metastatic niche, metastasis, immunothrombosis, immunodisruption, extracellular matrix remodeling, endothelial dysfunction, HMGB1, neutrophil extracellular traps, HIF-1α, matrix metalloproteinases, cancer microenvironment

The research team, led by Bingxuan Zheng, Junbo Li, Qi He, and senior author Chenguang Ding, established a mouse model of kidney transplantation in which donor kidneys were transplanted into unrelated recipients, recreating the immunological conflict that occurs in human transplantation. Rather than sampling the graft at a single moment, the investigators collected immune cells at multiple post-transplant stages, capturing the transition from acute rejection, when the immune assault is at its most violent, to the chronic phase, when fibrosis and gradual functional decline take hold. This longitudinal design is critical, because chronic rejection is not a static condition but a dynamic process in which the cellular players and their relationships shift over time. By sampling across that timeline, the researchers could watch the immune landscape evolve rather than merely snapshot its endpoint.

The technological core of the study is the pairing of single-cell RNA sequencing with single-cell ATAC sequencing. Single-cell RNA sequencing, or scRNA-seq, measures which genes are actively being transcribed in each individual cell, revealing the identity and functional state of thousands of cells simultaneously. Single-cell ATAC sequencing, or scATAC-seq, measures which regions of chromatin are physically accessible in each cell’s genome, exposing the regulatory landscape that determines which genes a cell could potentially activate. By analyzing both layers of information in the same immune cell populations, the researchers gained not just a census of which cells were present, but insight into the transcription factor programs driving their behavior. The team supplemented these core assays with computational tools including CellChat for mapping communication between cell types, RNA velocity and Monocle3 for inferring developmental trajectories, UMAP for visualization, and Weighted Gene Co-expression Network Analysis for identifying gene modules correlated with disease states.

Out of this multi-omic atlas emerged a striking finding: a late-stage, terminal-like state of macrophages defined by expression of the gene SPP1, which encodes secreted phosphoprotein 1, also known as osteopontin. These SPP1-positive macrophages were markedly enriched in chronically rejecting allografts compared with earlier stages. Macrophages are the tissue-resident scavengers and sentinels of the immune system, capable of enormous functional plasticity, and the study’s trajectory analyses suggest that the SPP1-positive population represents a terminal differentiation state that macrophages in the graft progressively adopt as rejection moves from acute inflammation toward chronic fibrosis. In other words, these cells appear to be not transient visitors but an end-stage product of immune evolution within the failing graft.

Position matters in tissue immunology, and the SPP1-positive macrophages were not merely abundant; they were central. When the researchers constructed ligand-receptor interaction networks to map how different immune cell populations communicate with one another, the SPP1-positive macrophages occupied a hub position in a macrophage-centered communication network. This means that many of the signaling conversations shaping the graft’s immune environment either originated from or passed through these cells. A cell at the center of such a network has outsized influence: it can recruit other immune cells, shape their differentiation, and coordinate collective behaviors such as tissue remodeling. The implication is that SPP1-positive macrophages may act as orchestrators of the fibrotic microenvironment rather than passive bystanders in a deteriorating graft.

The chromatin accessibility data added a crucial mechanistic dimension. Motif enrichment analysis of the scATAC-seq data revealed that the open regulatory regions in SPP1-positive macrophages were characterized by binding sites for CEBPβ, a transcription factor known as CCAAT/enhancer-binding protein beta. This finding identifies a CEBPβ-centered regulatory program as a candidate driver of the SPP1-positive macrophage state. Even more tellingly, the genes under this regulatory program were associated with sustained activation of extracellular matrix remodeling pathways. The extracellular matrix is the protein scaffold that gives tissue its structure, and its excessive deposition and remodeling is the defining feature of fibrosis. A regulatory program that keeps matrix-remodeling genes switched on in macrophages provides a plausible molecular link between chronic inflammation and the scarring that ultimately destroys graft function.

Perhaps the most intriguing cell-cell interaction identified in the study was a regulatory axis connecting SPP1-positive macrophages with CD8-positive tissue-resident memory T cells, abbreviated Trm cells. Tissue-resident memory T cells are a specialized population of T lymphocytes that take up long-term residence in tissues rather than circulating through blood and lymph nodes. In transplanted organs, they are increasingly recognized as persistent local actors that can sustain immune attack independently of the systemic immune system. The integrative ligand-receptor and pathway analyses in this study suggest that SPP1-positive macrophages and CD8-positive Trm cells engage in a predicted interaction network that is associated with the fibrosis-related immune remodeling characteristic of chronic rejection. This macrophage-T cell axis offers a concrete cellular partnership around which future mechanistic studies can be designed.

The significance of this work lies partly in its methodology and partly in its framing. Most studies of transplant rejection have relied on bulk tissue analysis, which averages signals across millions of cells and can mask the critical contributions of rare or state-specific populations. By resolving the graft immune environment at single-cell resolution across time, and by integrating gene expression with chromatin accessibility, the researchers have produced what they describe as a high-resolution longitudinal immune atlas of kidney allograft rejection. Within that atlas, SPP1-positive macrophages and the CEBPβ regulatory program stand out as candidate contributors to the fibrotic process. If validated, these targets could open therapeutic avenues that current immunosuppression does not address, since standard drugs broadly dampen lymphocyte activation but are not designed to reprogram macrophage differentiation or block matrix remodeling programs.

The authors are careful to emphasize the limits of what their study establishes. The work was performed in a mouse transplantation model, and the findings are framed as candidate regulators and predicted interaction networks rather than proven causal mechanisms. Functional validation, in which the activity of SPP1 or CEBPβ is experimentally manipulated to test whether fibrosis is altered, remains necessary. Human translation is an additional hurdle, since the immune environment of human transplanted kidneys may differ in important ways from the mouse model, and sampling human graft tissue at multiple time points presents practical and ethical challenges. The study was conducted under approved animal protocols at Xi’an Jiaotong University, and the researchers state that their findings offer a framework for future mechanistic and therapeutic investigations rather than immediate clinical application.

Even with those caveats, the study adds an important piece to the puzzle of why transplanted kidneys fail over the long term. Chronic rejection has long been viewed as an intractable, slowly accumulating process, but single-cell multi-omics is beginning to reveal that it has an identifiable cellular logic: specific immune cell states, governed by specific transcription factors, communicating through specific ligand-receptor pairs, drive the tissue toward scarring. By naming SPP1-positive macrophages, CEBPβ, and the CD8-positive tissue-resident memory T cell axis as central players, this atlas gives transplant immunologists a concrete set of hypotheses to test and, potentially, a new generation of therapeutic targets to pursue. For the hundreds of thousands of transplant recipients worldwide whose grafts slowly fail despite the best available immunosuppression, that kind of molecular specificity is exactly what the field has been waiting for.

Subject of Research: Single-cell multi-omics of immune cell dynamics during chronic rejection of transplanted kidneys

Article Title: Single-cell multi-omics characterization of rejection in transplanted kidneys reveals key cell types and candidate regulators of chronic rejection

Article References: Single-cell multi-omics characterization of rejection in transplanted kidneys reveals key cell types and candidate regulators of chronic rejection. (n.d.). https://doi.org/10.1186/s12967-026-09002-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09002-3

Keywords: kidney transplantation, chronic rejection, single-cell RNA sequencing, single-cell ATAC sequencing, macrophages, SPP1, CEBPβ, CD8-positive tissue-resident memory T cells, fibrosis, extracellular matrix remodeling, transplant immunology, multi-omics

The species at the center of the work, Quasipaa spinosa, is a large ranid frog prized in traditional cuisine and increasingly threatened in the wild, which makes understanding its reproductive biology more than an academic exercise. During the breeding season, males clasp females in a tight embrace called amplexus, and the chest spines are thought to help the male anchor himself to the often slippery female in fast-flowing stream water. But while the spines were long noted by field biologists as a striking secondary sexual trait, the structural and molecular machinery that builds them each year had never been systematically characterized. The new study set out to close that gap by combining classical histology with modern high-throughput molecular tools.

The team began by examining the chest skin of males at different points in the annual reproductive cycle: before breeding, during breeding, and after breeding had concluded. Using AB-PAS histological staining, a technique that distinguishes different classes of carbohydrates and secretory products in tissue sections, they revealed that the chest skin of Q. spinosa is not ordinary frog skin. It contains specialized glandular structures and a dermal framework unusually rich in collagen, the fibrous protein that gives skin its tensile strength. This pre-existing scaffold, the authors argue, provides the structural foundation on which the seasonal spines are subsequently built, rather than the spines arising de novo from undifferentiated tissue.

To understand what changes molecularly as the spines grow, the researchers performed quantitative proteomic analysis, comparing the protein content of chest skin across the pre-breeding, breeding and post-breeding stages, and also contrasting chest skin with abdominal skin from the same animals. The comparison identified large numbers of differentially expressed proteins, and the patterns were far from random. Principal component analysis showed that samples from each reproductive stage clustered distinctly, indicating that the chest skin undergoes a coordinated molecular remodeling program as the breeding season approaches, peaks, and passes. Among the protein categories that shifted most dramatically were components of the extracellular matrix, the fibrous and gel-like material that surrounds cells and gives tissues their shape.

That focus on the extracellular matrix, or ECM, is the conceptual heart of the paper. Pathway analysis of the differentially expressed proteins pointed to significant enrichment of ECM-related processes, including focal adhesion signaling and ECM-receptor interactions, the molecular junctions through which cells grip and remodel their surrounding scaffold. In practical terms, the data suggest that spine formation is not simply a matter of cells producing more keratin, but of the entire dermal environment being reorganized: collagen deposited and cross-linked, cell-matrix attachments adjusted, and tissue architecture reshaped to support the emerging keratinized structures. The spines, in this view, are the visible output of a deep remodeling of the skin’s connective-tissue framework.

The proteomic findings were reinforced at the level of gene expression. Using real-time quantitative PCR, the team validated the behavior of genes connected to the TGF-beta/Smad signaling pathway, a canonical regulatory cascade known from developmental biology to control cell growth, differentiation and the production of matrix components. The expression of these genes, along with others involved in matrix remodeling, changed dynamically across the reproductive cycle, rising and falling in step with the growth and subsequent regression of the spines. This concordance between protein-level and transcript-level evidence strengthens the conclusion that TGF-beta/Smad-mediated matrix remodeling is a central mechanism in the seasonal construction of the chest spines, and it offers a concrete molecular handle for future work on how amphibian secondary sexual characters are hormonally and environmentally regulated.

But the most consequential part of the study is its experimental test of function. Correlation between a showy trait and mating success is easy to claim and hard to prove, because attractive males may simply be older, larger or healthier in ways that independently boost their reproductive output. The researchers addressed this directly with reproductive competition experiments in which multiple males competed for access to females, combined with paternity testing based on microsatellite markers, short repetitive DNA sequences that act as genetic fingerprints and allow each offspring to be assigned to its biological father. The results were unambiguous: males whose chest spines were better developed sired more offspring than their rivals, and when the researchers artificially blunted the spines, those males’ reproductive success dropped.

This experimental design matters because it isolates the spines themselves as a causal factor in male reproductive success rather than a mere correlate. The paternity data, generated with SSR markers listed in the study’s supplementary tables, tie the physical condition of the spines directly to the number of offspring each male produced under competitive conditions. Together with the morphological measurements of spine phenotype recorded for each male, the experiments demonstrate that the seasonal spines function as a genuine sexually selected weapon or grip aid, most plausibly by improving a male’s ability to maintain amplexus with a female in turbulent stream environments where rivals and currents alike conspire to dislodge him.

Beyond its evolutionary interest, the work carries practical implications for conservation and aquaculture. Q. spinosa is heavily harvested across its range, and captive breeding programs are increasingly important both for commercial production and for population supplementation. The authors point out that chest spine development could serve as a simple, non-invasive visual indicator of male reproductive performance, allowing hatchery managers to select broodstock males with well-developed spines and thereby improve the genetic output of breeding groups. In wild populations under conservation management, the same trait could be used to gauge the reproductive fitness of males, linking an evolutionarily selected secondary sexual character to the day-to-day business of managing amphibian populations under pressure.

The study also opens broader questions about tissue plasticity in adult vertebrates. The idea that a region of skin can be repeatedly rebuilt each year, dismantled and reconstructed through extracellular matrix remodeling governed by a well-known developmental signaling pathway, resonates with research on antler regeneration, seasonal plumage and nuptial pads in other amphibians. By supplying a full pipeline from histology through proteomics and gene expression to functional paternity testing, the Zhejiang Normal University team has provided one of the most complete accounts to date of how a seasonal secondary sexual trait is built and why it matters. For a species whose survival increasingly depends on managed breeding, knowing that the spines on a male’s chest are both a molecular barometer of his readiness and a reliable predictor of his success as a father turns a curious anatomical feature into a practical conservation tool.

Subject of Research: Seasonal chest spine formation and its role in male reproductive success in the spiny frog Quasipaa spinosa

Article Title: Formation and reproductive significance of chest spines in Quasipaa spinosa

Article References: Peng, X., Piao, Z., Yi, Z., Min, C., Ben, L., & Rongquan, Z. (2026). Formation and reproductive significance of chest spines in Quasipaa spinosa. Frontiers in Zoology. https://doi.org/10.1186/s12983-026-00634-1

Image Credits: AI Generated

DOI: 10.1186/s12983-026-00634-1

Keywords: Quasipaa spinosa, chest spines, extracellular matrix remodeling, TGF-beta/Smad signaling, reproductive success, sexual selection, amphibian conservation, paternity testing, proteomics, secondary sexual traits, broodstock selection, Frontiers in Zoology

The technological revolution behind this reframing is worth appreciating. For most of the history of cancer biology, fibroblasts were studied in bulk, and their heterogeneity was invisible. The advent of single-cell RNA sequencing allowed researchers to profile the gene expression of individual fibroblasts within a tumor, revealing a startling mosaic of states. Spatial transcriptomics then added geography to the picture, showing where each fibroblast subtype resides relative to cancer cells, blood vessels, and immune cells. Multi-omics approaches that layer epigenetic, proteomic, and metabolic data on top of these maps have now made it possible to trace how fibroblast identities shift as tumors evolve. What has emerged is a taxonomy of recurring CAF programs: myofibroblastic CAFs marked by alpha-smooth muscle actin and contractile machinery, inflammatory CAFs that secrete cytokines such as interleukin-6 and CXCL12, antigen-presenting CAFs that display MHC class II molecules, interferon-response CAFs, and vascular-associated CAFs that hug the tumor’s blood supply.

Each of these states maps onto specific steps of the metastatic cascade, the multi-stage journey that carries a tumor cell from its primary site to a distant organ. The first step, local invasion, depends heavily on extracellular matrix remodeling. Myofibroblastic CAFs are master builders and demolition crews of the matrix, depositing collagen and cross-linking it with enzymes such as lysyl oxidase. This stiffened, realigned matrix does not merely form a physical scaffold; it generates mechanical cues that activate signaling pathways like FAK, YAP/TAZ, and ROCK in neighboring cancer cells, promoting epithelial-mesenchymal transition, the program by which epithelial tumor cells acquire motile, invasive properties. In pancreatic ductal adenocarcinoma, one of the most fibroblast-dense malignancies known, this dense stroma creates both a barrier to immune infiltration and a highway for invasion, illustrating how a single fibroblast program can simultaneously enable multiple metastatic steps.

Once tumor cells begin to move, they must evade the immune system, and here the review highlights a particularly insidious role for inflammatory CAFs. Through secretion of chemokines such as CXCL12 and CCL5, these fibroblasts recruit immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, while excluding or exhausting cytotoxic T lymphocytes that would otherwise kill tumor cells. The JAK/STAT and NF-kappa-B signaling pathways are central to this inflammatory choreography. Antigen-presenting CAFs add another layer of complexity: by expressing MHC class II molecules and, in some contexts, immune checkpoints such as PD-L2, they can directly modulate T cell activity in ways that remain incompletely understood but appear to tilt the local immune balance toward tolerance rather than attack. The net effect is a tumor microenvironment in which the stroma itself acts as an immunological shield.

Angiogenesis and vascular dissemination represent the next stage of the journey, and vascular-associated CAFs sit at this frontier. Positioned adjacent to tumor blood vessels, these cells interact with endothelial cells through vascular endothelial growth factor signaling and other pathways, supporting the formation of the leaky, disorganized vasculature that allows circulating tumor cells to enter the bloodstream. The review also describes how fibroblasts contribute to pre-metastatic niche formation, a phenomenon in which the primary tumor sends molecular advance parties, often packaged in extracellular vesicles, to distant organs such as the lung, liver, and bone. These signals condition resident fibroblasts in future metastatic sites, prompting them to remodel the matrix, secrete inflammatory mediators, and lay down a welcoming bed before any cancer cell arrives. Neutrophil extracellular traps and other stromal components recruited in this process further prepare distant tissues for colonization.

Metastatic colonization, the final and often fatal step, is where fibroblast support may matter most. Circulating tumor cells that survive in the bloodstream face a hostile foreign microenvironment, and the success or failure of their settlement depends on the stromal soil they encounter. The review emphasizes that the relationship between CAF states and metastatic progression is bidirectional: not only do distinct fibroblast states regulate specific steps of the cascade, but tumor-derived cues, inflammation, vascular signals, mechanical stress, metabolic conditions, and even therapy itself can reshape the composition and behavior of the fibroblast population. Chemotherapy, for example, can induce fibroblast state transitions that render the microenvironment more permissive to regrowth, a form of therapy-induced plasticity that may explain some treatment failures.

Perhaps the most consequential message of the review concerns the context-dependent duality of CAF function. Fibroblasts are not uniformly villainous. Certain fibroblast states and signals have been shown to restrain tumor growth, maintain tissue architecture, and support anti-tumor immunity. The authors point to clinical lessons from attempts at indiscriminate stromal depletion: in some settings, eliminating fibroblasts or blocking their hallmark signaling pathways worsened outcomes, unleashing more aggressive tumor behavior. The Sonic hedgehog pathway in pancreatic cancer became a cautionary tale in this regard, as its inhibition depleted stroma yet failed to improve, and in some models worsened, disease. Vitamin D receptor signaling, by contrast, has been associated with a tumor-restraining fibroblast phenotype, suggesting that reprogramming fibroblasts toward benign states may be more productive than killing them.

This insight underpins the precision therapeutic strategies the review advocates. Rather than viewing the stroma as a target for demolition, the authors propose selective modulation: identifying which fibroblast states dominate a given tumor, at a given metastatic stage, and intervening to disable their tumor-promoting functions while preserving or enhancing their tumor-restraining ones. Candidate approaches include inhibiting fibroblast activation protein on specific CAF subsets, blocking TGF-beta signaling in myofibroblastic CAFs, reprogramming inflammatory CAFs through agents such as all-trans retinoic acid, and exploiting metabolic vulnerabilities unique to particular fibroblast states. Emerging technologies such as CAR-T cells engineered against CAF-specific antigens and photodynamic therapy aimed at stromal compartments are also evaluated, with the authors stressing that each strategy must account for the risk of pushing plastic fibroblasts into more dangerous states.

The framework proposed by Li and colleagues integrates four dimensions that have often been studied in isolation: cellular state, spatial niche, metastatic stage, and phenotypic plasticity. In this view, a myofibroblastic CAF at the invasive front of a primary tumor, an inflammatory CAF clustered near excluded T cells, and a vascular-associated CAF lining a metastatic niche in the liver are not variations on a theme but distinct therapeutic targets requiring distinct interventions. The authors acknowledge that major questions remain unresolved, including how the reciprocal feedback loops between tumor cells and fibroblasts determine therapeutic response, and how best to monitor CAF state composition in patients over time. Single-cell and spatial technologies are increasingly being applied to clinical samples, raising the prospect that fibroblast-state profiling could one day guide stromal-targeted treatment decisions just as molecular profiling of tumor cells guides targeted therapy today.

For a field that has spent decades focused almost exclusively on the cancer cell itself, the message of this synthesis is quietly radical: the most abundant cell in many tumors is not a passive bystander but an active, plastic, and heterogeneous participant in metastasis, and the tools to map and manipulate it are finally at hand. If the metastasis-oriented framework proposed here proves correct, the future of anti-metastatic therapy may depend less on attacking tumor cells directly and more on negotiating with the fibroblasts that build their roads, guard their borders, and prepare their landing sites. Turning these cellular accomplices from collaborators into inhibitors, the review suggests, could transform how medicine confronts the spread of cancer, the process responsible for the majority of cancer deaths worldwide.

Subject of Research: Heterogeneity of cancer-associated fibroblasts and their roles in tumor metastasis and targeted therapy

Article Title: Heterogeneity of cancer-associated fibroblasts in tumor metastasis: mechanisms and precision therapeutic strategies

Article References: Li, Y., Chen, Y., Shen, X., Lou, J., Zhang, L., Qin, J., Pan, Y., & Wang, S. (2026). Heterogeneity of cancer-associated fibroblasts in tumor metastasis: mechanisms and precision therapeutic strategies. Molecular Cancer. https://doi.org/10.1186/s12943-026-02805-4

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02805-4

Keywords: cancer-associated fibroblasts, tumor metastasis, tumor microenvironment, extracellular matrix remodeling, single-cell RNA sequencing, spatial transcriptomics, pre-metastatic niche, epithelial-mesenchymal transition, angiogenesis, immune evasion, CAF plasticity, stromal-targeted therapy

The SASP is a staggeringly complex output. Senescent cells release pro-inflammatory cytokines such as IL-6, IL-8, TNF-α, and IL-1 family members; chemokines including CCL2, CCL5, and a host of CXCL proteins; growth factors such as VEGF, TGF-β, and HGF; matrix-degrading enzymes like MMP-2 and MMP-9; extracellular matrix fragments; and extracellular vesicles carrying microRNAs and proteins. The precise recipe depends on the cell’s origin, the trigger that induced senescence, and the local microenvironment, which helps explain why senescence can look heroically protective in one setting and dangerously corrosive in another. What is clear is that these secreted factors act both locally and systemically, allowing a relatively small population of arrested cells to exert outsized influence over the tumor microenvironment.

Timing turns out to be decisive. Experimental evidence indicates that an early SASP phase emerges within roughly two to four days after senescence induction, shaped by NOTCH-dependent signaling and enriched in TGF-β family members and matrix-remodeling proteins. By about seven to ten days, a more aggressive inflammatory program dominated by NF-κB-driven cytokines and chemokines takes over. In acute, transient phases, the SASP can function as a biological alarm bell: it recruits natural killer cells, cytotoxic CD8-positive T cells, macrophages, and dendritic cells that clear damaged or pre-malignant cells, and it can impose paracrine senescence on neighbors, forcing them into the same growth-arrested state. Preclinical liver and pancreatic cancer models show that this senescence surveillance genuinely suppresses tumor formation.

When senescence persists, however, the story darkens. Therapy-induced senescence, produced by genotoxic chemotherapy, radiation, and targeted drugs, leaves senescent cells lodged in tissues for months or years, chronically secreting inflammatory mediators. Studies estimate that markers of senescence appear in 31 to 66 percent of tumors after chemotherapy, and senescent cells also accumulate in surrounding healthy tissue. The resulting chronic SASP promotes extracellular matrix remodeling, neoangiogenesis, immune suppression, and cancer cell plasticity. In breast cancer models, IL-6 and IL-8 drive epithelial-mesenchymal transition, mammosphere formation, and stem-like phenotypes marked by CD44 and ALDH1. Senescent fibroblasts co-cultured with cancer cells enhance invasion, while residual tumor cells exposed to therapy-induced SASP develop measurable resistance to doxorubicin, cisplatin, and radiation.

Underneath this behavior lies an intricate regulatory network. Persistent DNA damage response signaling through ATM and ATR initiates the program, while the cGAS-STING pathway detects cytoplasmic chromatin fragments leaking from an unstable genome and triggers type I interferon responses. NF-κB acts as a transcriptional amplifier of inflammatory genes, NOTCH tunes the composition of the secretome between inflammatory and matrix-remodeling states, mTOR controls translational output, and JAK/STAT signaling sustains the whole circuit through IL-6-driven feed-forward loops. Crucially, no single pathway is sufficient to induce a full SASP on its own, which explains why the phenotype varies so dramatically across tumor types, senescence triggers, and patients—and why targeting it clinically is so challenging.

The immune consequences are especially consequential for modern oncology. Depending on context, the SASP can either enhance or sabotage immunotherapy. Acute senescence induced by CDK4/6 inhibitors in melanoma models produces a chemokine-rich secretome that draws dense infiltrates of CD4-positive and CD8-positive T cells, and interferon signaling triggered by such drugs improves antigen presentation and responsiveness to checkpoint blockade. Conversely, chronic SASP recruits myeloid-derived suppressor cells and regulatory T cells through CCL2, IL-1β, IL-6, and CSF-1, blunting the cytotoxic T-cell activity that immune checkpoint inhibitors depend upon. Senescent stromal cells in the breast, pancreas, and liver secrete VEGF, PDGF, and FGF family members that stimulate tumor vasculature, while senescent cancer-associated fibroblasts stiffen the extracellular matrix, activating mechanotransduction pathways that push tumors toward invasion and metastasis.

Therapeutically, researchers are pursuing two complementary strategies. Senolytics aim to kill senescent cells outright by exploiting the anti-apoptotic machinery—BCL-2 family signaling, PI3K/AKT, and FOXO4-p53 interactions—that keeps them alive. Navitoclax (ABT-263) has shown preclinical activity across ovarian, breast, lung, pancreatic, and blood cancers, though thrombocytopenia limits its clinical use. The dasatinib-plus-quercetin combination, the flavonoid fisetin, the FOXO4-DRI peptide, and procyanidin C1 broaden the arsenal, and novel drug-delivery systems such as galacto-oligosaccharide encapsulation are being engineered to reduce systemic toxicity. Senomorphics, by contrast, reshape the SASP without killing the cell: rapamycin suppresses SASP translation through mTOR, JAK inhibitors such as ruxolitinib blunt IL-6 and IL-8 signaling, and biologics including anakinra, siltuximab, and tocilizumab neutralize specific cytokines. Natural polyphenols like curcumin, apigenin, and resveratrol show senomorphic activity in preclinical systems by inhibiting NF-κB and mTOR pathways.

Timing, once again, complicates everything. Administered too early, senolytics or SASP suppression could destroy beneficial transient senescence that recruits immune clearance of damaged cells; administered too late, senomorphics may merely slow an already entrenched pro-tumor inflammatory state. Preclinical lymphoma models demonstrate that blocking NF-κB-dependent SASP during chemotherapy actually diminishes treatment benefit by preventing NK-cell recruitment, while ablating radiation-senescent cells in the brain microenvironment reduces glioblastoma recurrence. These opposing results underscore that senescence-targeted interventions must be sequenced carefully relative to the primary therapy, tuned to tumor type, and calibrated to the senescence burden carried by each patient—a burden that rises sharply with age and obesity, both of which amplify pro-tumorigenic SASP signaling.

Translating these insights into the clinic will also require better biomarkers. SASP components such as IL-6 and IL-8 overlap heavily with inflammatory molecules produced by immune and epithelial cells during infection or injury, so single-cytokine measurements are unreliable. Emerging single-cell and spatial multi-omics technologies, together with computational resources like the SASP Atlas, now allow researchers to map distinct senescent cell states—inflammatory, fibrotic, metabolic, and immune-modulatory—within intact tumors, and multi-marker panels combining secreted factors with p16, p21, and DNA damage markers are being validated for monitoring therapy response. For now, the review’s authors conclude, senolytics and senomorphics should be regarded as investigational rather than established cancer treatments. Yet the underlying message is unambiguous: the same biological program that once looked like a simple off switch for cancer may prove to be one of oncology’s most powerful and nuanced therapeutic levers, provided clinicians learn precisely when to silence it, when to exploit it, and when to eliminate it altogether.

Subject of Research: Senescence-associated secretory phenotype remodeling of the tumor microenvironment and its implications for cancer progression and senotherapeutic treatment strategies

Article Title: A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

Article References: Pallatt, S., Nambidi, S., Banerjee, A., & Pathak, S. (2026). A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy. Cancer Reports, 9(9), Article e70682. https://doi.org/10.1002/cnr2.70682

Image Credits: AI Generated

DOI: 10.1002/cnr2.70682

Keywords: cellular senescence, SASP, tumor microenvironment, senolytics, senomorphics, therapy-induced senescence, cancer immunotherapy, IL-6, extracellular matrix remodeling, cancer-associated fibroblasts, biomarkers, drug resistance

The research team, led by Jian Liu, Jin Bai, Cheng Deng, and Zukai Wu of the Third People’s Hospital of Xinjiang Uygur Autonomous Region and Union Hospital of Huazhong University of Science and Technology, set out to identify the mechanosensitive genes that behave abnormally in the vascular smooth muscle cells of patients with Marfan syndrome. These cells form the muscular middle layer of the aortic wall, and their behavior is exquisitely sensitive to the mechanical environment. When the extracellular matrix deteriorates, as it does in Marfan syndrome, the mechanical cues reaching these cells are distorted, and the cells respond with a maladaptive program of remodeling, proliferation, and inflammation that further weakens the vessel.

To find the molecular switches behind this response, the team re-analyzed publicly available transcriptomic data from the dataset GSE128101, comparing gene expression in aortic vascular smooth muscle cells derived from Marfan syndrome patients with those from healthy donors. The screen identified 436 differentially expressed genes. Functional enrichment analysis revealed that these genes clustered around several interconnected themes: extracellular matrix remodeling, mechanotransduction—the process by which cells convert mechanical stimuli into biochemical signals—inflammatory signaling, and cytoskeletal organization. In other words, the genetic signature of Marfan aortopathy is not simply a story of structural collapse, but of cells actively misreading their mechanical world.

Narrowing the field from hundreds of candidate genes to the most plausible mechanosensitive regulators required a layered computational strategy. The researchers applied protein-protein interaction analysis to map how the differentially expressed genes connect functionally, used pathway enrichment to highlight biological themes, and then employed a statistical feature-selection method known as minimum redundancy maximum relevance, which favors genes that are strongly associated with the disease while avoiding overlap with one another. The top-ranked candidate to emerge from this pipeline was TRPV4, a calcium-permeable ion channel well known in the mechanobiology literature for its role in translating stretch, pressure, and matrix stiffness into intracellular calcium signals. A second channel, TRPM5, was also identified as an overlapping candidate.

The team then moved from computation to the laboratory. Using quantitative reverse-transcription polymerase chain reaction on primary aortic medial smooth muscle cells isolated from Marfan syndrome patients and from organ donors, they confirmed that both TRPV4 and TRPM5 are expressed at significantly higher levels in the patient-derived cells. Immunofluorescence imaging added a further layer of evidence: in the Marfan-derived cells, TRPV4 showed enhanced localization at the cell membrane, the position from which the channel is best placed to sense mechanical forces and admit calcium. The patient cells also displayed elevated expression of inflammatory genes, suggesting that the channel’s overabundance coincides with an activated inflammatory state.

To test whether TRPV4 is merely a bystander or an active driver of this dysfunctional behavior, the researchers manipulated the channel’s expression in primary human aortic smooth muscle cells. When they overexpressed TRPV4, the cells became more proliferative, closed scratch wounds more rapidly in migration assays, and secreted higher levels of inflammatory cytokines. Critically, the overexpression also increased phosphorylation of components of the NF-κB pathway, a canonical inflammatory signaling cascade whose activation in the vessel wall is a recognized hallmark of aneurysm progression. When the researchers silenced TRPV4 using small interfering RNA, the opposite pattern emerged: proliferation slowed, wound closure diminished, cytokine secretion fell, and NF-κB phosphorylation decreased.

These results position TRPV4 as a leading mechanosensitive candidate associated with the vascular smooth muscle cell remodeling and inflammatory activation that characterize Marfan aortopathy. The finding fits within a broader and rapidly growing body of evidence implicating mechanosensitive ion channels in vascular disease. Recent studies have shown that deletion of endothelial TRPV4 protects the heart from pressure overload-induced hypertrophy, that deficiency of endothelial TRPV4 channels ameliorates experimental abdominal aortic aneurysm, and that the TRPV4-YAP axis mediates cytoskeletal and extracellular matrix remodeling in other tissues. TRPV4 has also been linked to vascular calcification and aortic stiffening, suggesting that the channel sits at a convergence point for multiple forms of arterial pathology.

The mechanistic logic of the new findings is compelling. In a healthy aorta, fibrillin-1-rich elastic fibers transmit mechanical load smoothly to smooth muscle cells, which maintain a quiescent, contractile phenotype. In Marfan syndrome, the fragmented matrix alters the pattern of force transmission, and the study suggests that TRPV4, abundant and membrane-enriched in the patient cells, converts this distorted mechanical input into pathological calcium entry. Calcium influx through TRPV4 would then activate downstream signaling, including NF-κB, driving the cells toward a synthetic, proliferative, and inflammatory state. This phenotypic switching of smooth muscle cells is widely regarded as a central event in aneurysm formation, and a channel that couples mechanical dysfunction to inflammatory activation is an attractive node for intervention.

The authors are careful to frame their conclusions as exploratory. The study relied on re-analysis of a public dataset with a limited number of samples, and although the qRT-PCR validation in primary patient cells strengthens the case, larger cohorts will be needed to confirm the consistency of the TRPV4 signature across the genetically and clinically heterogeneous Marfan population. The functional experiments were conducted in primary human aortic smooth muscle cells in vitro, which capture important aspects of the disease but cannot fully reproduce the complex mechanical and humoral environment of a living aneurysmal aorta. Direct mechanistic assays—for example, calcium imaging under controlled mechanical stimulation, or pharmacological blockade of TRPV4 in Marfan animal models—will be required to establish causality and to determine whether the channel is a viable biomarker or therapeutic target.

Even with those caveats, the study adds a significant piece to the mechanobiological puzzle of Marfan syndrome. Current clinical management of the Marfan aorta relies heavily on imaging surveillance, blood pressure control, and, in many cases, prophylactic surgical repair. Drugs such as beta-blockers and angiotensin receptor blockers slow but do not halt aortic dilation, and the search for molecular targets that address the underlying cellular dysfunction remains intense. If TRPV4’s role is confirmed in larger studies and disease models, the channel could offer a way to intervene at the point where mechanical failure is translated into cellular pathology—potentially allowing clinicians to quiet the inflammatory, remodeling program before the aorta reaches a dangerous diameter. In a condition where the difference between stability and catastrophe is measured in millimeters, a molecular handle on that translation would be a welcome advance.

Subject of Research: Mechanosensitive gene programs, particularly the TRPV4 calcium channel, in Marfan syndrome aortopathy

Article Title: TRPV4 is Associated with a Marfan Syndrome-Related Mechanosensitive Gene Program in Aortic Smooth Muscle Cells

Article References: TRPV4 is Associated with a Marfan Syndrome-Related Mechanosensitive Gene Program in Aortic Smooth Muscle Cells. (n.d.). https://doi.org/10.1007/s10528-026-11447-6

Image Credits: AI Generated

DOI: 10.1007/s10528-026-11447-6

Keywords: Marfan syndrome, TRPV4, mechanotransduction, vascular smooth muscle cells, aortic aneurysm, inflammation, NF-κB pathway, extracellular matrix remodeling, calcium channel, aortopathy, Biochemical Genetics, gene expression

FBP1 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate into fructose-6-phosphate, making it the rate-limiting enzyme of gluconeogenesis. In recent years it has attracted attention in oncology, where it suppresses glycolysis by restraining the HIF-1α pathway and acts as a protein phosphatase that dephosphorylates targets such as histone H3 and telomerase reverse transcriptase. But its role in diabetic wound healing had never been systematically characterized. To close that gap, the team built an in vitro model of the diabetic wound microenvironment using HaCaT keratinocytes, the workhorse cells of epidermal renewal, exposed to methylglyoxal. Methylglyoxal is a highly reactive α-dicarbonyl metabolite that accumulates in hyperglycemic tissue and drives the formation of irreversible advanced glycation end-products, fueling collagen cross-linking and microvascular damage. Dose-response experiments identified 400 micromolar methylglyoxal as a concentration that significantly suppressed keratinocyte proliferation, impaired colony formation, and crippled cell migration in scratch and transwell assays, faithfully mimicking the cellular defects seen in chronic diabetic wounds.

With the model established, the researchers turned to transcriptome-wide RNA sequencing to find the molecular drivers of dysfunction. The analysis revealed 1,375 upregulated and 724 downregulated genes in methylglyoxal-treated cells, with gene ontology annotations pointing to defects in cytoplasmic and plasma membrane components and KEGG enrichment implicating type 1 diabetes, diabetic complications, and growth regulation. Among the differentially expressed genes, one stood out: FBP1 was significantly upregulated by methylglyoxal exposure. Functional validation quickly established the enzyme as a negative regulator of repair. Keratinocytes engineered to overexpress FBP1 using lentiviral vectors showed markedly reduced proliferation and migration, while cells treated with FBP1-specific small interfering RNA proliferated and migrated more vigorously. MTT and colony formation assays quantified the effect, confirming at the statistical level of P less than 0.01 that FBP1 is a significant inhibitor of the two cellular behaviors on which wound closure most depends.

Having identified the target, the team went hunting for an inhibitor. Using the crystal structure of human FBP1 as a template, they virtually screened a library of 2,100 natural products, first filtering candidates through Lipinski’s Rule of Five and then docking them into the enzyme’s fructose-6-phosphate binding pocket with the LibDock and CDOCKER algorithms in Discovery Studio. From the top-ranked hits, in vitro enzymatic testing singled out asiatic acid, a pentacyclic triterpenoid from Centella asiatica long used in traditional wound care. Molecular docking showed asiatic acid nesting snugly in the catalytic pocket, forming hydrogen bonds with ARG25, MET30, and LYS112 and hydrophobic contacts with ALA24, ARG140, and MET177, at a docking energy of −7.15 kcal/mol. Its measured inhibitory potency, an IC50 of 2.50 micromolar, actually exceeded that of adenosine monophosphate, the enzyme’s endogenous inhibitor. A cellular thermal shift assay, in which treated cells are heated across a temperature gradient, confirmed that asiatic acid binds FBP1 directly inside living cells, stabilizing the protein between 48 and 62 degrees Celsius.

Mechanistically, asiatic acid’s benefits flowed through a well-defined signaling cascade. Western blotting showed that methylglyoxal suppressed phosphorylation of AKT and mTOR along with downstream HIF-1α and uPAR, proteins that together drive keratinocyte proliferation and migration. Treatment with 20 micromolar asiatic acid restored the p-AKT/AKT and p-mTOR/mTOR ratios and lifted HIF-1α levels 1.7-fold and uPAR levels 2.3-fold. Importantly, the compound left total FBP1 expression unchanged, demonstrating that it works through direct enzymatic inhibition rather than transcriptional repression. Phalloidin staining added a striking visual dimension: methylglyoxal and FBP1 overexpression fragmented the actin cytoskeleton, and asiatic acid partially restored filamentous actin organization, linking FBP1 inhibition to the cytoskeletal mechanics of cell migration.

But asiatic acid has a practical flaw: its high polarity limits skin permeability. The chemists responded with rational design. They acetylated hydroxyl groups on the molecule’s A-ring to balance solubility and membrane permeability, then conjugated the scaffold to three different hydrogen sulfide donors. Hydrogen sulfide, the most recently recognized gasotransmitter alongside nitric oxide and carbon monoxide, has well-documented pro-healing credentials, from AMPK-mediated angiogenesis to preservation of mitochondrial membrane potential in stressed keratinocytes. Among the resulting conjugates, one derivative, AA4, outperformed the rest by a wide margin, enhancing proliferation of methylglyoxal-injured keratinocytes more than tenfold compared with the parent compound at equivalent concentrations.

AA4 proved to be more than a simple inhibitor. In vitro enzymatic assays confirmed that it retained asiatic acid’s FBP1-blocking power, with an IC50 of 2.38 micromolar. Yet western blots revealed that AA4 also lowered FBP1 protein levels, and the mechanism proved to be chemistry of an unusual kind. When the team scavenged hydrogen sulfide using oxidized glutathione, FBP1 expression rebounded, and the reducing agent dithiothreitol reversed AA4’s effect, lifting FBP1 levels nearly fivefold. Together these experiments indicate that AA4’s hydrogen sulfide release promotes FBP1 protein degradation through persulfidation, a sulfur-based post-translational modification that marks the enzyme for breakdown. The result is a dual attack: asiatic acid directly jams the enzyme’s catalytic activity while the released gas erases the protein itself. Rescue experiments underscored the significance, with AA4 restoring 82 percent of methylglyoxal-impaired migration and 3.3-fold higher proliferation in FBP1-overexpressing cells.

The derivative’s most important gift to wounded tissue, however, may be keeping keratinocytes alive. RNA sequencing of AA4-treated cells showed 748 upregulated and 1,422 downregulated genes relative to injured controls, with strong enrichment of apoptotic pathways and a signature of increased Bcl-2 and decreased FBP1. Flow cytometry, Hoechst nuclear staining, and TUNEL assays confirmed that AA4 dramatically reduced apoptosis in both methylglyoxal-challenged and FBP1-overexpressing cells. At the protein level, injury models showed a 5.8-fold increase in the pro-apoptotic Bax/Bcl-2 ratio along with elevated cleaved Caspase-3 and PARP; AA4 treatment raised Bcl-2 3.5-fold, cut Bax by 69.3 percent, and reduced cleaved Caspase-3 and PARP by 64.4 percent. When hydrogen sulfide was scavenged, this protection vanished, and in cells where FBP1 had been knocked down, AA4 offered no further benefit, proving its anti-apoptotic effect depends entirely on the presence of its target.

The decisive test came in living animals. The team induced diabetes in mice with streptozotocin, created full-thickness dorsal wounds, and applied AA4 in a Pluronic F-127 hydrogel that released more than 80 percent of its payload within 12 hours. The results were striking. By day seven, wounds treated with 1 milligram per milliliter AA4 had closed by 90.7 percent, compared with just 50 percent in untreated diabetic controls, and the 3 milligram per milliliter formulation achieved 95.5 percent closure, outperforming both native asiatic acid and adenosine monophosphate. Histology revealed thicker stratum corneum, enhanced epidermal regeneration, and denser collagen deposition, while immunohistochemistry confirmed suppression of FBP1 in the healing tissue. The treatment also calmed the inflammatory storm that stalls diabetic wounds: mRNA levels of IL-1β, IL-6, IL-8, and TNF-α, all elevated in diabetic wounds, fell after AA4 application, and macrophage markers shifted from the pro-inflammatory M1 phenotype, marked by CD86, toward the pro-healing M2 phenotype, marked by CD206. Using the methylene blue method, the researchers verified that AA4 released hydrogen sulfide sustainably, restoring wound tissue gas levels to 45.9 micromolar and reversing the hydrogen sulfide deficiency characteristic of diabetes.

The study, whose authors say the work was conducted with ethical approval and without competing interests, is notable both for the target it unveils and for the strategy it embodies. By pairing unbiased transcriptomics with structure-guided drug design, the researchers moved from a differentially expressed gene to a chemically optimized, dual-mechanism therapeutic in a single program. FBP1, long studied in the contexts of gluconeogenesis and tumor metabolism, now emerges as a druggable node in regenerative medicine, while AA4 demonstrates how conjugating a natural product with a gasotransmitter donor can overcome pharmacological limitations. The specific persulfidation sites on FBP1 and the degradation pathways involved remain to be mapped, and clinical translation will require further development. But for patients whose wounds linger for months or years, the prospect that a derivative of a traditional medicinal plant, supercharged with a signaling gas, could more than double healing rates within a week offers a genuinely new direction, one in which precision target discovery and rational molecular engineering finally converge on one of diabetes’ most stubborn complications.

Ovarian aging is one of the most striking examples of biological decline in the human body. Unlike most organs, which renew themselves over decades, the ovary carries a fixed, non-renewable pool of follicles, each of which houses an immature oocyte. From mid-life onward this pool dwindles both through ovulation and through atresia, the process by which follicles degenerate. The endocrine consequences are profound: declining anti-Müllerian hormone and estrogen levels, rising follicle-stimulating hormone, irregular cycles, reduced fertility and, eventually, menopause, which itself raises the risk of osteoporosis, cardiovascular disease and neurodegeneration. While oxidative stress, DNA damage accumulation, telomere attrition and chronic low-grade inflammation have all been implicated in this process, the physical environment in which ovarian follicles live has received far less attention.

The research team began with a deceptively simple question: does the mechanical character of the ovarian stroma—the dense meshwork of collagen, fibronectin and other matrix proteins that surrounds follicles—change as the ovary ages, and if so, does that change matter? Using atomic force microscopy to probe living tissue at the nanoscale, the researchers measured the stiffness of ovarian tissue across the reproductive lifespan in mouse models and in human samples. They found a consistent and dramatic trend: aged ovaries were significantly stiffer than young ones, with matrix stiffening beginning well before overt signs of follicle depletion. Histological and second-harmonic-generation imaging revealed that this stiffening was accompanied by excessive deposition and abnormal cross-linking of collagen fibers, producing a denser, more rigid scaffold around the follicles that had once been cradled in a soft, compliant microenvironment.

Mechanobiology offers a rationale for why this matters. Cells continuously sense the elasticity of their surroundings through integrin receptors and the cytoskeleton, and matrix stiffness feeds back into gene expression, proliferation, differentiation and survival. Stiff environments have been shown to drive fibrosis and dysfunction in organs ranging from liver to heart to brain. In the ovary, follicles depend on exquisitely coordinated communication between the oocyte, the surrounding granulosa cells and the stromal theca; the investigators reasoned that a rigidifying stroma could distort these interactions, impairing follicle activation, maturation and survival. Indeed, when young ovarian follicles were cultured on artificially stiffened substrates, they showed reduced growth, compromised granulosa cell function and elevated markers of cellular stress, while follicles maintained on soft matrices retained their vigor. Conversely, softening the environment of aged follicles partially restored their developmental competence.

Having established that stiffness itself is functionally consequential, the team searched for the molecular mechanism that drives it. Transcriptomic and proteomic profiling of young and aged ovarian stroma pointed unambiguously to interleukin-11, a pro-inflammatory cytokine of the IL-6 family that signals through the IL-11 receptor and the downstream JAK-STAT3 pathway. IL-11 is best known as a fibrotic mediator: in lung, liver and kidney fibrosis models it acts as a central switch that instructs fibroblasts to proliferate, deposit extracellular matrix and activate contractile programs. The new work shows that IL-11 levels rise in the aging ovary in parallel with matrix stiffening, that stromal fibroblasts respond to IL-11 by upregulating collagen synthesis and maturation enzymes that cross-link and stiffen the matrix, and that this response is mediated by canonical STAT3-dependent transcriptional changes. In effect, IL-11 converts the ovarian stroma into a scar-like, rigid environment as the organism ages.

The causal experiments were the most striking part of the study. When the researchers administered a neutralizing antibody against IL-11 to aging female mice, or deleted the IL-11 signaling axis genetically, ovarian stiffness declined, collagen architecture normalized, and follicle numbers were preserved at levels far exceeding those of untreated age-matched controls. Treated animals retained larger pools of primordial and growing follicles, showed improved ovarian hormonal output with healthier estrous cyclicity, and produced more oocytes in response to superovulation, several of which developed into healthy embryos after fertilization. Perhaps most compelling, the treatment window was not restricted to early life: initiating IL-11 blockade in mid-aged females, after substantial follicle loss had already occurred, still measurably slowed the trajectory of ovarian decline, suggesting a realistic therapeutic horizon rather than an intervention that must begin before reproductive maturity.

The study also dissected the cellular choreography underlying the effect. Using single-cell RNA sequencing and fate-mapping approaches, the authors tracked how stromal fibroblasts transition with age into an activated, matrix-producing state reminiscent of the myofibroblasts seen in organ fibrosis. IL-11 signaling emerged as a master regulator of this transition: in its presence, fibroblasts accumulated, secreted abundant collagen and lysyl-oxidase-family cross-linking enzymes, and physically remodeled the follicular niche; in its absence, the fibroblast population remained quiescent and the matrix retained its youthful architecture. Granulosa cells, in turn, responded to the softer niche with improved proliferation, lower senescence markers and better support of oocyte meiotic quality, closing the loop between stromal mechanics and gamete health.

Experts in reproductive biology, who were not involved in the work, describe it as a conceptual advance because it relocates ovarian aging partly outside the follicle itself. Much of the field has focused on intrinsic oocyte damage or on the exhaustion of the follicle pool as a simple counting problem. The new findings imply that the niche is an active participant that can accelerate or slow that depletion, and that its mechanical state is a modifiable variable. This reframing echoes recent discoveries in other aging tissues, where extracellular matrix stiffening has emerged as a common, and pharmacologically actionable, feature of late-life decline. It also aligns with clinical observations: women with endometriosis, pelvic inflammatory disease or ovarian surgery, conditions associated with fibrosis and adhesions, often experience earlier declines in ovarian reserve, a correlation that the mechanistic model now helps to explain.

Translating these results to humans will require careful work. IL-11-blocking antibodies have already been developed and tested in early-phase clinical trials, primarily for fibrotic diseases such as pulmonary fibrosis, with a tolerability profile that the authors cite as encouraging for reproductive applications. Nevertheless, cytokines of this class serve important functions in immunity, platelet biology and tissue repair, and any fertility-oriented intervention would need to demonstrate safety for both the woman and the developing oocyte across potentially months or years of treatment. Questions also remain about timing and dosing, about whether IL-11 levels in blood or follicular fluid could serve as biomarkers to identify women most likely to benefit, and about how much of human ovarian aging is driven by matrix mechanics versus other converging insults such as mitochondrial dysfunction and genomic damage. Mouse ovaries, with their much larger follicle pools and shorter reproductive spans, are imperfect proxies for human reproductive physiology.

Even so, the implications are broad. An estimated one in six people worldwide now experiences infertility, and the age of first childbirth continues to rise across high-income countries, making the preservation of ovarian function a major public health concern. Beyond fertility, delaying ovarian senescence would postpone the hormonal transition of menopause and could reduce the cascade of age-associated conditions linked to estrogen loss. The authors suggest that IL-11 pathway modulation could eventually complement existing strategies—such as oocyte cryopreservation and in vitro maturation—by protecting the ovary itself, and possibly by improving the quality of the ovarian microenvironment into which follicles are retrieved or transplanted. More generally, the study adds the ovary to the growing list of organs in which mechanotransduction, the conversion of physical cues into biochemical signals, shapes the aging process. As the authors conclude, targeting IL-11-dependent matrix stiffness offers a proof of concept that the biophysical milieu of an aging tissue is not merely a consequence of time’s passage but a cause of it—and, crucially, one that can be modified. Whether a simple anti-fibrotic injection will one day extend the reproductive window remains to be proven in the clinic, but the ovaries of antibody-treated mice growing old in a softer, younger world provide the most persuasive evidence yet that this is a serious scientific proposition rather than wishful thinking.

The work builds on a decade of genetic evidence. Genome-wide association studies have repeatedly linked variants near the desmoplakin gene, DSP, to susceptibility to idiopathic pulmonary fibrosis, and independent work has shown that a functional variant, rs2076295, regulates desmoplakin expression in airway epithelial cells. Desmoplakin variants have also been associated with a distinctly fibrotic and inflammatory form of heart muscle disease, suggesting that this protein does more than glue cells together. What has been missing, however, is a mechanistic account of how reduced desmoplakin in the alveolar epithelium could translate into the collagen deposition, matrix stiffening, and epithelial dysfunction that define pulmonary fibrosis. The new study, led by first author Pooja Singh with senior author Ritushree Kukreti, sets out to close that gap.

To do so, the researchers used small interfering RNA to silence DSP expression in A549 cells, an adenocarcinoma-derived human alveolar epithelial cell line that is a workhorse of pulmonary fibrosis modeling. The consequences of losing desmoplakin were immediate and multifaceted. The cells underwent hallmarks of epithelial-to-mesenchymal transition, the process by which epithelial cells shed their polarized, adhesive identity and acquire migratory, matrix-producing characteristics. Cell migration increased, epithelial permeability rose, and the expression of fibrotic and extracellular matrix-associated genes climbed. Among the genes upregulated were COL1A1, which encodes the alpha-1 chain of type I collagen, the dominant structural protein of fibrotic scars, and MMP9, a matrix metalloproteinase that degrades and reshapes the extracellular matrix. In fibrotic lungs, the balance between matrix-degrading enzymes and their inhibitors is famously disrupted, and the appearance of these genes after DSP loss places desmoplakin squarely upstream of matrix remodeling.

To identify the pathway responsible, the team turned to the STRING database and mapped the known interaction partners of desmoplakin, then performed pathway enrichment analysis on that network. One signal rose above the rest: the canonical Wnt/β-catenin pathway, an ancient developmental signaling cascade whose reactivation in adult tissues is a well-documented feature of idiopathic pulmonary fibrosis. Prior studies have shown that functional Wnt signaling is increased in fibrotic human lungs and that β-catenin–dependent transcription supports the survival and migration of alveolar epithelial cells after injury. The enrichment analysis suggested that desmoplakin might act as a brake on this program—and that removing the brake would allow fibrotic signaling to run unchecked.

The mechanistic validation that followed is where the study becomes technically interesting. Desmosomes are not merely mechanical fasteners; their component proteins participate in signaling crosstalk, most notably through plakoglobin, also known as γ-catenin. Plakoglobin is a close molecular relative of β-catenin: both are armadillo-family proteins that compete for overlapping binding sites at junctions, and both can, in principle, enter the nucleus and engage T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors. Crucially, plakoglobin acts as a transcriptional antagonist of β-catenin in several tissues. Landmark work in cardiomyocytes showed that nuclear plakoglobin suppresses canonical Wnt/β-catenin signaling, and that its loss underlies the pathology of arrhythmogenic cardiomyopathy. The New Delhi team hypothesized that an analogous arrangement governs the alveolar epithelium.

The experiments supported that hypothesis. Using cycloheximide chase assays, which block new protein synthesis and allow researchers to follow the decay of existing proteins over time, the researchers found that loss of desmoplakin destabilized desmosomal complexes and accelerated the degradation of plakoglobin. At the same time, β-catenin turnover was reduced, meaning the signaling-competent catenin persisted longer in the cell. Quantitative PCR and western blotting confirmed the corresponding changes in transcript and protein abundance, and immunofluorescence microscopy revealed increased accumulation of β-catenin in the nucleus—the compartment where it acts as a transcriptional co-activator. Luciferase reporter assays, in which cells are engineered to glow when TCF/LEF-driven transcription occurs, demonstrated that this nuclear β-catenin was functionally active, driving enhanced TCF/LEF-dependent transcription. The downstream consequence was elevated expression of extracellular matrix genes, including COL1A1 and MMP9, tying the junctional protein loss directly to the fibrotic transcriptional output.

The team then tested the circuit from the opposite direction. When they overexpressed desmoplakin, Wnt/β-catenin signaling and fibrotic gene expression were suppressed, consistent with desmoplakin acting as a homeostatic restraint on the pathway. And when they pharmacologically inhibited Wnt/β-catenin signaling in cells lacking desmoplakin, the increases in ECM-associated gene expression were attenuated—strong evidence that the pathway is not merely correlated with the fibrotic phenotype but is causally required for it. Together, the gain-of-function, loss-of-function, and rescue experiments sketch a coherent model: desmoplakin stabilizes the desmosomal scaffold that retains plakoglobin; plakoglobin, in turn, competes with and restrains β-catenin; when desmoplakin disappears, plakoglobin degrades, β-catenin accumulates in the nucleus, TCF/LEF transcription surges, and the cell begins manufacturing the molecular ingredients of scar tissue.

The findings resonate with related observations in other organs and cell types. Plakophilin-2, another desmosomal protein, has been shown to restrain TGF-β1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes, and desmoplakin-deficient zebrafish models of cardiac disease show Wnt/β-catenin abnormalities that can be rescued by genetic and pharmacological intervention. The lung appears to follow the same logic: the structural apparatus of epithelial adhesion doubles as a signaling hub, and its erosion converts mechanical vulnerability into biochemical reprogramming. This dual role may explain why genetic variants that subtly lower desmoplakin expression—without abolishing it entirely—could predispose individuals to fibrosis over decades, particularly when combined with environmental insults such as microaspiration, smoke exposure, or viral injury.

The clinical implications are tantalizing but deliberately hedged. Available antifibrotic drugs for idiopathic pulmonary fibrosis slow disease progression modestly, and there is broad agreement that new targets are urgently needed. If reduced desmoplakin function is a driver of fibrotic initiation in susceptible individuals, then preserving desmosomal integrity, stabilizing plakoglobin, or dialing down β-catenin activity in the alveolar epithelium could represent alternative therapeutic strategies. Wnt pathway inhibitors are already in development for cancer and other fibrotic diseases, and the current results suggest a specific epithelial context in which such inhibitors might be beneficial. Conversely, the study complicates the picture for regenerative medicine, because β-catenin signaling is also required for lung development and epithelial repair; any therapeutic manipulation would need to distinguish between protective, transient signaling during wound healing and the chronic, dysregulated activation that drives fibrosis.

The authors are careful to frame their conclusions within the limits of the model system. A549 cells, while convenient and widely used, are a cancer-derived line with alveolar epithelial characteristics rather than genuine primary type II alveolar epithelial cells, and the entire study was conducted in vitro. Whether desmoplakin loss activates the same plakoglobin–β-catenin axis in primary human alveolar epithelial cells, in three-dimensional organoid cultures, or in animal models of fibrosis remains to be demonstrated. The team states explicitly that the disease relevance of the pathway will require validation in primary human alveolar epithelial cells and in vivo models. Nonetheless, by connecting a genetically validated IPF risk gene to a specific signaling mechanism and a concrete transcriptional output—collagen and matrix-remodeling enzymes—the study converts a statistical association into a testable biological hypothesis. It reframes the alveolar epithelium’s adhesive machinery as an active participant in epithelial–matrix crosstalk, and it suggests that the earliest seeds of pulmonary fibrosis may be planted not in the fibroblast, as long assumed, but in the structural proteins that hold the lung’s most vulnerable cells together.

The stakes are considerable for the poultry industry. Modern laying hens are biological machines optimized for extraordinary output, producing an egg nearly every day, and that productivity depends on an ovary in constant, high-turnover motion. Follicles are recruited, grown, and ovulated in rapid succession, a process that demands enormous energy, a rich blood supply, and tight hormonal orchestration. It is also a process exquisitely vulnerable to reactive oxygen species. When oxidative stress tips the balance, follicles die off in a process called atresia, hormone levels fall, and laying performance plummets. Because consumers and regulators increasingly demand reductions in synthetic additives, the search for natural, sustainable interventions has become urgent within the One Health framework that links animal, human, and environmental well-being.

To model that stress in a controlled way, the team injected hens with tert-butyl hydroperoxide, or tBHP, a chemical oxidant widely used to induce reproducible oxidative damage in animal studies. Thirty healthy Hy-Line Brown hens were randomly divided into three groups of ten. A control group received a basal diet and saline injections. A stressed group received the basal diet plus tBHP injections every four days for 28 days. The third group received the same tBHP challenge but ate a diet supplemented with 0.6 percent Acer truncatum leaf extract, or ATLE, a preparation exceptionally rich in polyphenols and flavonoids. Over the four-week trial, the researchers tracked egg production, feed efficiency, ovarian anatomy, blood hormones, antioxidant markers, angiogenic factors, and, crucially, the full transcriptomic landscape of the ovary.

The results were striking. Oxidative stress alone drove laying rates down, pushed the feed conversion ratio up, and reduced average daily feed intake, exactly the pattern seen when hens divert resources from reproduction toward survival. It also shrank the pool of hierarchical follicles, the large preovulatory follicles destined for ovulation, and lowered the ovarian stroma index, a measure of the functional tissue supporting follicle development. Histological sections revealed more atretic follicles and necrotic inflammatory foci in the stressed ovaries. Serum concentrations of luteinizing hormone and growth hormone fell, disrupting the hypothalamic-pituitary-gonadal axis that governs follicle recruitment. In hens fed the maple leaf extract, however, nearly all of these parameters rebounded. Laying rate and feed efficiency recovered, hierarchical follicle numbers and stroma index were preserved, and LH and GH concentrations rose significantly compared with the stressed, unsupplemented birds.

The molecular engine behind this rescue appears to be the Nrf2 pathway, the master switch of cellular antioxidant defense. Under normal conditions, the transcription factor Nrf2 is held inactive by its suppressor Keap1; when oxidative pressure rises, Nrf2 escapes, migrates to the nucleus, and switches on a battery of cytoprotective genes. In the stressed hens, the expression of Nrf2 and its downstream targets, including SOD3, GPX3, PRDX4, GSR, and CAT, was significantly suppressed. ATLE supplementation reversed this shutdown, and the biochemical consequences were measurable in both blood and ovarian tissue: superoxide dismutase and catalase activities climbed, while malondialdehyde, a lipid peroxidation product that serves as a fingerprint of oxidative damage, dropped. The authors propose that the extract’s flavonoids and polyphenols act either by directly scavenging reactive oxygen species or by modulating the Keap1-Nrf2 interaction, consistent with prior work showing that resveratrol, theabrownin, and other plant compounds preserve reproductive function through the same axis.

Perhaps the most novel finding concerns blood vessels. Follicle growth is angiogenesis-dependent: each developing follicle must be wrapped in a network of new capillaries that deliver nutrients, oxygen, and hormones. Oxidative stress damages vascular endothelial cells and disrupts hypoxia signaling, suppressing key angiogenic factors such as vascular endothelial growth factor and angiopoietin 1. In the stressed hens, ovarian protein levels of VEGF, ANGPT1, and HIF-1α all fell, along with mRNA expression of VEGFA, ANGPT1, ANGPT2, ITGA5, and MMP9. ATLE supplementation restored these factors, suggesting the extract did more than passively mop up free radicals; it appeared to actively support the reconstruction of a functional vascular scaffold within the ovary. This aligns with known actions of related phytochemicals, such as quercetin promoting angiogenesis through PI3K/Akt signaling and resveratrol stimulating endothelial migration via SIRT1/HIF-1α pathways.

The transcriptomic analysis tied these threads together into a systems-level picture. RNA sequencing of ovarian tissue identified 4,191 differentially expressed genes under oxidative stress and 1,373 genes shifted by ATLE supplementation. The overlap was striking: 91.9 percent of the genes altered by the extract were also among those damaged by oxidative stress, and more than 88 percent of the enriched Gene Ontology terms overlapped between the two comparisons. In other words, the extract appeared to reverse the damage almost point for point. Pathway analysis showed that both injury and repair converged on extracellular matrix organization, focal adhesion, and ECM-receptor interaction, the structural infrastructure that allows endothelial cells to migrate and vascular networks to form. Genes encoding collagens, laminin, fibronectin, and the VEGF receptor KDR were all suppressed by stress and restored by the extract, indicating a coordinated remodeling of the ovarian microenvironment back toward homeostasis.

The study is not without caveats, which the authors acknowledge candidly. The trial lasted only four weeks with ten hens per group, a design well suited to illuminating mechanisms under acute chemical stress but insufficient to predict performance across full commercial laying cycles. ATLE is a complex mixture, and the specific compounds responsible for the effects were not isolated. Most importantly, it remains unresolved whether the extract stimulates angiogenesis directly or whether vascular recovery is simply a secondary benefit of reduced oxidative damage; the interplay between Nrf2 and VEGF signaling has been noted in other contexts, including preeclampsia research. The authors call for endothelial cell models to disentangle cause from effect and for longer trials in production settings.

Even with those limitations, the findings carry real weight for animal agriculture and beyond. They demonstrate that a nutritional intervention can act on multiple signaling axes at once, fortifying antioxidant defenses through Nrf2 while simultaneously preserving the vascular and extracellular matrix architecture that follicles require. They also reinforce a growing theme in reproductive biology: ovarian vascular health, long overlooked, is a central determinant of fertility, and its degradation may underlie reproductive aging in species far beyond the hen. For poultry producers, ATLE now has a scientific rationale as a natural feed additive that combines antioxidant action with microenvironment regulation. For researchers, the study provides a template for evaluating how phytochemical cocktails reshape tissue microenvironments, not merely how they quench radicals. And for anyone following the broader movement toward sustainable, plant-based interventions in animal health, the purpleblow maple has just earned a prominent place on the list of plants worth watching.

The choice of tBHP as the oxidative challenge deserves note. Unlike chronic stressors such as heat or high stocking density, this organic peroxide generates intracellular free radicals directly and predictably, allowing researchers to isolate the biochemical cascade from the many confounders of real-world husbandry. That precision explains why the model is a workhorse in poultry reproductive studies, even though the damage it inflicts is more acute than what a commercial flock typically experiences.

The dual emphasis on Nrf2 and VEGF also reflects an emerging understanding that these pathways are not independent. Reactive oxygen species at moderate levels normally participate in hypoxia-inducible signaling, and when oxidative stress overwhelms that system, both antioxidant gene transcription and angiogenic factor production collapse together. A supplement that restores one axis while sparing the other would leave follicles metabolically protected but still starved of blood supply. The coordinated recovery of SOD and CAT activities alongside VEGF, ANGPT1, and HIF-1α in the supplemented hens suggests the polyphenol mixture acted upstream of both branches, a property single-molecule antioxidants often lack.

The extracellular matrix findings extend this picture beyond the vasculature. Focal adhesion and ECM-receptor interaction pathways provide the physical substrate on which granulosa cells and endothelial cells migrate during follicle growth, and their disruption by stress, followed by restoration of fibronectin, collagen, and the VEGF receptor KDR, indicates repair of tissue architecture rather than mere biochemical correction. For feed manufacturers, the practical implication is that a standardized leaf extract could be formulated into layer diets during vulnerable periods, such as the peak-to-post-peak transition, when oxidative burdens on the ovary are greatest. For comparative biologists, the study adds to evidence that ovarian microvascular integrity is a conserved determinant of fertility, making the laying hen a useful model for nutritional approaches to reproductive resilience in mammals as well.

Subject of Research: Use of Acer truncatum leaf extract as a dietary feed additive to protect laying hen ovarian function from oxidative stress via Nrf2-mediated antioxidant defense and VEGF-mediated angiogenesis.

Article Title: Dietary supplementation of Acer truncatum leaf extract alleviates oxidative-stress induced impairment of ovarian function in laying hens via Nrf2-mediated antioxidant defense and VEGF-mediated angiogenesis

Article References: Qin, K., Ma, J., Gao, M., Liu, Y., & Yang, X. (2026). Dietary supplementation of Acer truncatum leaf extract alleviates oxidative-stress induced impairment of ovarian function in laying hens via Nrf2-mediated antioxidant defense and VEGF-mediated angiogenesis. Stress Biology, 6(1), Article 60. https://doi.org/10.1007/s44154-026-00329-x

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00329-x

Keywords: Acer truncatum leaf extract, laying hens, oxidative stress, Nrf2 pathway, angiogenesis, VEGF, ovarian function, poultry nutrition, reproductive hormones, extracellular matrix remodeling, feed additives, transcriptomics